New hope for advanced breast cancer patients: expanded access to investigational drug leronlimab
NCT ID NCT07536815
First seen Apr 29, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This program offers investigational leronlimab to adults with advanced or metastatic triple-negative breast cancer who have run out of standard treatment options. Participants must have confirmed HR-/HER2- cancer and have progressed on prior therapy. The goal is to provide potential disease control when no other treatments are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oregon Oncology Specialists
AVAILABLESalem, Oregon, 97301, United States
Conditions
Explore the condition pages connected to this study.